An implementation plan for the Europe-wide introduction of measures to protect patients from fake or “falsified” medicines has been released by The European Medicines Agency. Safety features to be added to medicines packaging include a 2-D barcode and an anti-tampering device.

Falsified medicines could contain ingredients, including active ingredients, which are of low quality or in the wrong dosage, and could potentially put patients’ health at risk, says the EMA. The measures are being taken to help prevent falsified medicines from entering the legal supply chain and posing a risk to patients and to ensure that any medicines bought online are supplied through verified sources.

The new measures must be introduced for all medicines for human use across Europe by February 2019 – three years time.

It has previously been suggested the pharmacies may be required to scan the 2-D barcode.

Martin Sawer, executive director of the UK’s Healthcare Distribution Association, representing organisations in the medicines supply chain, commented: “It is good news to finally see the publication of the Delegated Regulation that sets the clock ticking in the UK and other EU member states.”

He welcomed the model chosen for the initiative, after long debate in Europe. “Alternatives would have placed unnecessary burdens on the supply chain, including delays in being able to supply life-saving medicines speedily to patients,” he said.

Recommended

Hunt announces new measures to tackle drug errors

Measures are needed in hospitals, general practice, pharmacies and care homes to curb as many as 237 million drug errors...

Harness research to improve dementia care, report urges

A new report from Alzheimer’s Society sets out a roadmap for how to harness research to ensure quality of life for...